课题基金 / 基金详情

Signal transduction of RANK and Toll-like receptor in alveolar bone destruction

Signal transduction of RANK and Toll-like receptor in alveolar bone destruction
RANK和Toll样受体在牙槽骨破坏中的信号转导
批准号:
15390565
负责人:
UDAGAWA Nobuyuki
金额:
$9.47万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (B)
财政年份:
2003
资助国家:
日本
项目状态:
已结题
起止时间:
2003 至 2004

项目摘要

项目成果

UDAGAWA Nobuyuki的其他基金

相似基金

相关文献

中文摘要
翻译
在细菌引起的炎症性疾病中,脂多糖是一种有效的骨吸收刺激剂。细菌脂蛋白/脂肽也是病原体特异性的分子模式。toll样受体4 (TLR4)被认为是LPS的信号受体。TLR6和TLR2复合物可识别二酰基脂肽。TLR的信号级联与IL-1受体的信号级联相似,因为TLR和IL-1受体都使用MyD88作为共同的信号分子。Toll-IL-1受体结构域适配器诱导的干扰素-γ (TRIF)介导的信号也被证明参与了lps诱导的myd88独立通路。使用MyD88缺失(MyD88^<-/->)小鼠和TRIF缺失(TRIF^<-/->)小鼠,我们研究了MyD88和TRIF在破骨细胞分化和功能中的作用。LPS、二酰基脂肽(DL)和IL-1可刺激TRIF^<-/->小鼠的成骨细胞和造血细胞的共培养,而MyD88^<-/->小鼠则无此作用。MyD88^<-/-> m . More ice和TRIF^<-/->小鼠骨髓造血细胞在RANKL + m - csf作用下相似地分化为破骨细胞。LPS、DL和IL-1可刺激TRIF^<-/->成骨细胞中RANKL mRNA的表达,而对MyD88^<-/->成骨细胞无影响,提示成骨细胞中只有MyD88介导的信号对RANKL的表达起重要作用。这一发现特别有趣,因为myd88依赖途径和trif依赖途径都是巨噬细胞中lps诱导的细胞因子产生所必需的。事实上,LPS不能刺激TRIF^<-/->骨髓巨噬细胞产生IL-6。而脂多糖可以刺激TRIF^<-/->成骨细胞产生IL-6。LPS和IL-1可提高TRIF^<-/->破骨细胞的存活率,但对MyD88^<-/->破骨细胞无作用。DL不支持破骨细胞存活,因为破骨细胞中缺乏TLR6。trf相关适配分子(TRAM)在trf介导的信号通路中起重要作用。有趣的是,巨噬细胞同时表达TRIF和TRAM mRNA,而成骨细胞和破骨细胞仅表达TRIF mRNA。成骨细胞中脂多糖诱导的RANKL和IL-6表达以及破骨细胞存活不需要trif介导的信号,这可能与成骨细胞和破骨细胞中缺乏TRAM表达有关。骨组织形态学测量显示MyD88^<-/->小鼠表现为低周转骨质疏松症,骨吸收和骨形成减少。这些结果表明,MyD88介导的信号对于IL-1和TLR配体诱导的破骨细胞发生和功能至关重要,MyD88在生理上参与骨转换。少
英文摘要
LPS is a potent stimulator of bone resorption in inflammatory diseases caused by bacteria. Bacterial lipoprotein/lipopeptides are also pathogen-specific molecular patterns. Toll-like receptor 4 (TLR4) is identified as the signaling receptor for LPS. The complex of TLR6 and TLR2 recognizes diacyl lipopeptide. The signaling cascade of TLR is similar to that of IL-1 receptors, because both TLR and IL-1receptors use MyD88 as a common signaling molecule. Toll-IL-1 receptor domain-containing adapter inducing interferon-γ (TRIF)-mediated signals are also shown to be involved in LPS-induced MyD88-independent pathway. Using MyD88-deficient (MyD88^<-/->) mice and TRIF-deficient (TRIF^<-/->) mice, we examined roles of MyD88 and TRIF in osteoclast differentiation and function. LPS, diacyl lipopeptide (DL) and IL-1 stimulated osteoclastogenesis in co-cultures of osteoblasts and hemopoietic cells obtained from TRIF^<-/-> mice but not MyD88^<-/-> mice. Bone marrow hemopoietic cells from MyD88^<-/-> m … More ice and TRIF^<-/-> mice similarly differentiated into osteoclasts in response to RANKL plus M-CSF. LPS, DL and IL-1 stimulated RANKL mRNA expression in TRIF^<-/-> osteoblasts but not MyD88^<-/-> osteoblasts, suggesting that only MyD88-mediated signal in osteoblasts was important for RANKL expression in response to those factors. This finding was particularly interesting, because both MyD88-dependent and TRIF-dependent pathways are essential for LPS-induced cytokine production in macrophages. Indeed, LPS failed to stimulate IL-6 production in TRIF^<-/-> bone marrow macrophages. But, LPS could stimulate IL-6 production in TRIF^<-/-> osteoblasts. LPS and IL-1 enhanced the survival of TRIF^<-/-> osteoclasts but not MyD88^<-/-> osteoclasts. DL did not support the survival of osteoclasts, because of the lack of TLR6 in osteoclasts. TRIF-related adaptor molecule (TRAM) was shown to be essentially involved in the TRIF-mediated signaling pathway. Interestingly, macrophages expressed both TRIF and TRAM mRNAs, while osteoblasts and osteoclasts expressed only TRIF mRNA. The fact that TRIF-mediated signals are not required for LPS-induced RANKL and IL-6 expression in osteoblasts and for osteoclast survival may be related to the lack of TRAM expression in osteoblasts and osteoclasts. Bone histomorphometry showed that MyD88^<-/-> mice exhibited low turnover osteoporosis with reduced bone resorption and formation. These results suggest that the MyD88-mediated signal is essential for the osteoclastogenesis and function induced by IL-1 and TLR ligands, and that MyD88 is physiologically involved in bone turnover. Less
期刊论文(50)
专著(0)
科研奖励(0)
会议论文
Itoh K.et al.: "LPS promotes the survival of osteoclasts via toll-like receptor 4, but cytokine production of osteoclasts in response to LPS is different from that of macrophages."Journal of Immunology. 170・7. 3688-3695 (2003)
Itoh K.等人:“LPS通过Toll样受体4促进破骨细胞的存活,但破骨细胞响应LPS的细胞因子产生与巨噬细胞不同。”免疫学杂志170・7。 2003)
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
MyD88 but not TRIP is essential for osteoclastogenesis induced by lipopolysaccharide, diacyl lipopeptide and IL-1α.
MyD88 而不是 TRIP 对于脂多糖、二酰基脂肽和 IL-1α 诱导的破骨细胞生成至关重要。
DOI: --
发表时间: 2004
期刊: J Exp Med 200
影响因子: --
作者: [Sato N, et al.]
通讯作者: et al.
骨吸収と骨形成の共役機構
骨吸收与骨形成的耦合机制
DOI: --
发表时间: 2004
期刊: 腎と骨代謝 17・2
影响因子: --
作者: [清水武彦, 韓娟, 岡本春憲, 新井陽子, 前田隆秀, Takahisa TOYAMA et al., Sato N et al., 中村美どり 他]
通讯作者: 中村美どり 他
Suda K.et al.: "Suppression of osteoprotegerin expression by prostaglandin E_2 is crucially involved in LPS-induced osteoclast formation."Journal of Immunology. 172・4. 2504-2510 (2004)
Suda K.等人:“前列腺素E_2对骨保护素表达的抑制对于LPS诱导的破骨细胞形成至关重要。”免疫学杂志172·4(2004)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
共 21 条
    Exploration of seeds for development of a new drug targeting Bone-Vascular-Spleen axis
    • 批准号:
      25670793
    • 项目类别:
      Grant-in-Aid for Challenging Exploratory Research
    • 资助金额:
      $2.41万
    • 财政年份:
      2013
    • 负责人:
      UDAGAWA Nobuyuki
    • 依托单位:
    Analysis of bone remodeling mechanism between osteoblasts and osteoclasts for the alveolar bone regeneration
    • 批准号:
      24390417
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $11.73万
    • 财政年份:
      2012
    • 负责人:
      UDAGAWA Nobuyuki
    • 依托单位:
    Basic research on development of new treatment of alveolar bone regeneration
    • 批准号:
      21390498
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $11.73万
    • 财政年份:
      2009
    • 负责人:
      UDAGAWA Nobuyuki
    • 依托单位:
    Elucidation of the regulated mechanism of bone metabolism by osteoclastic transcytosis.
    • 批准号:
      19390476
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $12.15万
    • 财政年份:
      2007
    • 负责人:
      UDAGAWA Nobuyuki
    • 依托单位:
    国内基金
    海外基金
    异类叶升麻苷通过阻断TLR4二聚体化抑制MyD88/TRIF信号通路减轻重症急性胰腺炎急性肺损伤的作用机制研究
    • 批准号:
      81904041
    • 项目类别:
      青年科学基金项目
    • 资助金额:
      21.0万元
    • 批准年份:
      2019
    • 负责人:
      王彬
    • 依托单位:
    异类叶升麻苷通过阻断TLR4二聚体化抑制MyD88/TRIF信号通路减轻重症急性胰腺炎急性肺损伤的作用机制研究
    天然免疫STING/MAVS/TRIF/MyD88信号通路在HBsAg阳性母亲婴儿乙肝疫苗无/弱应答中的作用
    • 批准号:
      81872677
    • 项目类别:
      面上项目
    • 资助金额:
      57.0万元
    • 批准年份:
      2018
    • 负责人:
      冯永亮
    • 依托单位:
    针刺干预创伤性脑损伤及其对TLR4/MyD88/TRIF介导的小胶质细胞活化的调控机制研究
    • 批准号:
      81704156
    • 项目类别:
      青年科学基金项目
    • 资助金额:
      20.0万元
    • 批准年份:
      2017
    • 负责人:
      朱明敏
    • 依托单位: